Analyst Price Targets — BEAM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 2:20 pm | — | RBC Capital | $26.00 | $30.83 | TheFly | Beam Therapeutics price target raised to $26 from $22 at RBC Capital |
| February 20, 2026 11:29 am | — | Canaccord Genuity | $74.00 | $27.88 | TheFly | Beam Therapeutics initiated with a Buy at Canaccord |
| January 21, 2026 12:44 pm | William Pickering | Tudor Pickering | $41.00 | $31.00 | StreetInsider | Beam Therapeutics Inc (BEAM) PT Raised at Bernstein Following Positive Regulatory Update |
| January 20, 2026 11:44 pm | — | Bernstein | $41.00 | $30.97 | TheFly | Beam Therapeutics price target raised to $41 from $37 at Bernstein |
| January 7, 2026 5:40 am | Michael Yee | UBS | $28.00 | $28.34 | StreetInsider | UBS Starts Beam Therapeutics Inc (BEAM) at Neutral |
| November 24, 2025 1:11 pm | — | Evercore ISI | $35.00 | $23.32 | TheFly | Beam Therapeutics initiated with an Outperform at Evercore ISI |
| October 9, 2025 3:43 pm | — | Jefferies | $41.00 | $27.86 | TheFly | Beam Therapeutics initiated with a Buy at Jefferies |
| May 7, 2025 12:18 pm | Debjit Chattopadhyay | Guggenheim | $55.00 | $15.99 | TheFly | Beam Therapeutics price target lowered to $55 from $78 at Guggenheim |
| March 3, 2025 2:37 pm | — | Scotiabank | $25.00 | $25.10 | TheFly | Beam Therapeutics price target raised to $25 from $24 at Scotiabank |
| January 7, 2025 12:50 pm | William Pickering | Tudor Pickering | $37.00 | $27.08 | StreetInsider | Bernstein SocGen Group Upgrades Beam Therapeutics Inc (BEAM) to Outperform |
Latest News for BEAM
Beam Therapeutics Inc. is rated a Buy for its leadership in proprietary base-editing gene therapy, targeting significant unmet needs in hematology and liver diseases. BEAM's risto-cel shows superior efficacy in sickle cell disease, but commercial success hinges on overcoming conditioning protocol challenges and competing with Vertex/Crispr's head start. The liver-targeted BEAM-302 program demonstrates strong early…
Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029.
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
Beam announced a loss per share of 10 cents, far surpassing the consensus estimate of a loss of 99 cents. Additionally, the company reported revenue of $114.11 million, dramatically exceeding expectations of $12.567 million.
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.09 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BEAM.
U.S. House Trading
No House trades found for BEAM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.